Search results | MorphoSys

Reports

Partnering Agreements with Morphosys

The Partnering Agreements with Morphosys report provides an in-depth insight into the partnering interests and activities of one of the worlds leading biopharma companies.

Insights

MorphoSys: Partnering activity 2009-2014

MorphoSys, a leader in antibody drug discovery, has emerged as a top 50 big biotech company with its product pipeline and partnering strategy.

MorphoSys M&A deals 2009-2014

MorphoSys has announced only one acquisition in the past 5 years.

Morphosys: Clear leaders in antibody generation

Morphosys is a leading biotechnology developing therapeutic antibodies for a range of different indications.

MorphoSys: Company profile

Current Agreements Deal Analysis Update : September 2014

This month we provide you with an overview of life science deal making activity, covering partnering, M&A and financing in August 2014.

Celgene; Going ‘green’ for transformative technologies

Celgene is a big pharmaceutical company discovering and developing medical treatments indicated for cancer and other inflammatory conditions.

Current Agreements Deal analysis Update : July 2013

This month we are providing you with an overview of deal analysis in the life sciences, covering partnering and M&A in June 2013

Events

Sorry, your search returned no results.


Deals

Morphosys acquires Lanthio Pharma

MorphoSys has acquired all outstanding shares of the Dutch biopharmaceutical company Lanthio Pharma B.V.

Morphosys regains MOR202 rights from Celgene

MorphoSys has regained rights to MOR202 from Celgene

Morphosys acquires lanthipeptide technology from Lanthio Pharma

MorphoSys and Lanthio Pharma acquires of Lanthio Pharma’s lanthipeptide technology, which will be used for drug discovery by MorphoSys.

Emergent BioSolutions sign a biotech licensing deal with MorphoSys

Emergent BioSolutions announced a biotech licensing agreement for the joint development and commercialization of Emergent’s preclinical bi-specific antibody, ES414, targeting prostate cancer.

Merck and Morphosys sign a cancer pharma deal

MorphoSys and Merck have signed an pharma deal to discover and develop therapeutic antibodies against undisclosed immune checkpoints.

MorphoSys raises $126 million in private financing

MorphoSys has raised gross proceeds of approximately EUR 84 million in a private placement financing via an accelerated book building procedure

MorphoSys and Celgene pharma deals for Oncology drug co-development and co-marketing in $818 million deal

MorphoSys, a big pharma, and Celgene, a big pharma and big biotech, announced pharma deals to jointly develop MOR202 globally and to co-promote MOR202 in Europe.

GSK seals global pharma licensing development agreement with MorphoSys

MorphoSys have entered into a global pharma licensing agreement with GlaxoSmithKline to develop and commercialize MOR103

MorphoSys signs manufacturing agreement with Boehringer

MorphoSys AG and Boehringer Ingelheim have announced the signing of a biopharmaceutical manufacturing agreement for therapeutic antibodies.

MorphoSys AG signs long term alliance with Pfizer on sloning technology technology platform

MorphoSys AG has announced the signing of a non-exclusive license and technology transfer agreement between its subsidiary Sloning BioTechnology GmbH and Pfizer.

cpbannerad300x150new2gif
rauconbadgejpg
e78banner300x150animgif
cabannerad300x150new4gif
e79banner300x150gif
e78banner300x150animgif